Market Place
Sourcing Support
Sensei Shrinks Workforce By 65% As Layoff Warning Comes To Pass
14 Nov 2025 //
FIERCE BIOTECH
Sensei Bio Initiates Strategic Review To Boost Shareholder Value
30 Oct 2025 //
GLOBENEWSWIRE
Sensei Shows Durable PFS for Solnerstotug in PD-L1 Tumors
17 Oct 2025 //
GLOBENEWSWIRE
Sensei Bio To Host Virtual Kol Event On Solnerstotug In Pd-(l)1
23 Sep 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present at H.C. Wainwright Conference
03 Sep 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports Q2 2025 Financials, Updates
05 Aug 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present Phase 1 Solnerstotug Data
30 Jul 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
13 Jun 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports Q1 2025 Results and Clinical Update
06 May 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics Reports 2024 Financial Results & Progress
28 Mar 2025 //
GLOBENEWSWIRE
Sensei Bio Reports Positive Data For Solnerstotug In PD-(L)1 Tumors
27 Mar 2025 //
GLOBENEWSWIRE
Sensei Bio to Participate in Oppenheimer’s Healthcare Conference
04 Feb 2025 //
GLOBENEWSWIRE
Sensei Bio Shares Update, Key Milestones In Corporate Progress
08 Jan 2025 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Attend Citi 2024 Global Healthcare Conf.
27 Nov 2024 //
GLOBENEWSWIRE
Sensei lays off 46% of staff, closes site to fund cancer trial
14 Nov 2024 //
FIERCE BIOTECH
Sensei Bio Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics to Present at Upcoming Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Sensei Biotherapeutics To Present SNS-103 Data At Conference
04 Sep 2024 //
GLOBENEWSWIRE
Sensei Bio Phase 1 Promising: Sns-101 Dose Escalation Data Shown
23 May 2024 //
GLOBENEWSWIRE
Sensei to Present SNS-101 Phase 1 Topline Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Sensei Announces Nature Communi Describing MOA of SNS-101 Selectively Targeting
04 Apr 2024 //
GLOBENEWSWIRE
Sensei Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101
23 Oct 2023 //
GLOBENEWSWIRE
Sensei Announces Initiation of Combination Arm for Phase 1/2 Study of SNS-101
27 Sep 2023 //
GLOBENEWSWIRE
Sensei Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile
21 Sep 2023 //
GLOBENEWSWIRE
Sensei Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101
01 Jun 2023 //
GLOBENEWSWIRE
Sensei Announces IND Clearance by U.S. FDA Enabling Ph1 Initiation for SNS-101
20 Apr 2023 //
GLOBENEWSWIRE
Sensei to Present Data for SNS-101,Conditionally Active VISTA-blocking Antibody
14 Feb 2023 //
GLOBENEWSWIRE
Sensei Bio Signs CRADA with the NCI to Develop Plan for SNS-101
06 Feb 2023 //
GLOBENEWSWIRE
